Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Source: Senate LDA
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
SUPPORT for Patients and Communities Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
SUPPORT for Patients and Communities Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · third_quarter · Q3
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · second_quarter · Q2
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · first_quarter · Q1
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · third_quarter · Q3
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office